A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Clinical trial NCT06109272 · RECRUITING

Trial details

NCT number: NCT06109272
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2024-01-11
Primary completion: 2030-09-01
Enrollment: 660

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.